» Articles » PMID: 37398678

The Role of Lysosomal Peptidases in Glioma Immune Escape: Underlying Mechanisms and Therapeutic Strategies

Overview
Journal Front Immunol
Date 2023 Jul 3
PMID 37398678
Authors
Affiliations
Soon will be listed here.
Abstract

Glioblastoma is the most common primary malignant tumor of the central nervous system, which has the characteristics of strong invasion, frequent recurrence, and rapid progression. These characteristics are inseparable from the evasion of glioma cells from immune killing, which makes immune escape a great obstacle to the treatment of glioma, and studies have confirmed that glioma patients with immune escape tend to have poor prognosis. The lysosomal peptidase lysosome family plays an important role in the immune escape process of glioma, which mainly includes aspartic acid cathepsin, serine cathepsin, asparagine endopeptidases, and cysteine cathepsins. Among them, the cysteine cathepsin family plays a prominent role in the immune escape of glioma. Numerous studies have confirmed that glioma immune escape mediated by lysosomal peptidases has something to do with autophagy, cell signaling pathways, immune cells, cytokines, and other mechanisms, especially lysosome organization. The relationship between protease and autophagy is more complicated, and the current research is neither complete nor in-depth. Therefore, this article reviews how lysosomal peptidases mediate the immune escape of glioma through the above mechanisms and explores the possibility of lysosomal peptidases as a target of glioma immunotherapy.

Citing Articles

Human Melanoma and Glioblastoma Cells Express Cathepsins Supporting Reovirus Moscow Strain Infection.

Ammour Y, Nikolaeva E, Sagimbaeva O, Shamsutdinov P, Astapenko A, Zhelaeva Y Viruses. 2025; 16(12.

PMID: 39772250 PMC: 11680368. DOI: 10.3390/v16121944.


The interplay between metal ions and immune cells in glioma: pathways to immune escape.

Li J, Mao Y, Chen S, Ye R, Fei Y, Li Y Discov Oncol. 2024; 15(1):348.

PMID: 39134820 PMC: 11319581. DOI: 10.1007/s12672-024-01229-0.


Nanoparticles for efficient drug delivery and drug resistance in glioma: New perspectives.

Liu J, Yang F, Hu J, Zhang X CNS Neurosci Ther. 2024; 30(5):e14715.

PMID: 38708806 PMC: 11071172. DOI: 10.1111/cns.14715.

References
1.
Zhang M, Jia Y, Li P, Qiao Y, Han K . New Protocol-Guided Exploitation of a Lysosomal Sulfatase Inhibitor to Suppress Cell Growth in Glioblastoma Multiforme. J Med Chem. 2021; 64(12):8599-8606. DOI: 10.1021/acs.jmedchem.1c00559. View

2.
Zhou Y, Wang W, Chen N, Wang L, Huang J . Research progress of anti-glioma chemotherapeutic drugs (Review). Oncol Rep. 2022; 47(5). PMC: 8990335. DOI: 10.3892/or.2022.8312. View

3.
Janji B, Hasmim M, Parpal S, Berchem G, Noman M . Firing up the cold tumors by targeting Vps34. Oncoimmunology. 2020; 9(1):1809936. PMC: 7480807. DOI: 10.1080/2162402X.2020.1809936. View

4.
Zhang H, Xu X, Xu R, Ye T . Drug repurposing of ivermectin abrogates neutrophil extracellular traps and prevents melanoma metastasis. Front Oncol. 2022; 12:989167. PMC: 9484526. DOI: 10.3389/fonc.2022.989167. View

5.
He C, Klionsky D . Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet. 2009; 43:67-93. PMC: 2831538. DOI: 10.1146/annurev-genet-102808-114910. View